Skip to main content
Terminated

Study of Pemetrexed for Second-Line Pancreas Cancer

By April 24, 2017No Comments

Condition

Pancreas Cancer

Estimated Enrollment: 17

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: IIT2007022|2007-022

Study First Received: March 17, 2009

Last Updated: December 7, 2015

Estimated Primary Completion Date: July 2009

 

Primary Outcome Measures:

Progression-free Survival|Objective Response|CA 19-9 Response|Number of Participants With Adverse Events

Sponsors and Collaborators:

Georgetown University|Eli Lilly and Company

Website Link: https://ClinicalTrials.gov/show/NCT00864513

Leave a Reply